Peripartum cardiomyopathy: Current therapeutic perspectives

  • Sabrina D. Phillips
  • Carole A. Warnes


Peripartum cardiomyopathy is a rare condition of unclear etiology that accounts for an important percentage of pregnancy-related deaths. Deaths from peripartum cardiomyopathy can be attributed to profound left ventricular failure, thromboembolic events, or arrhythmia. Prompt recognition of the condition, initiation of appropriate medical management, collaboration with perinatology for delivery management, referral to cardiac transplant centers when necessary, and counseling regarding future pregnancies is required for a successful outcome. Patients should be diagnosed by clinical evaluation and echocardiography. After establishing left ventricular dysfunction, a standard heart failure medical regimen should be instituted. Hospitalization should be considered for patients with class III or greater symptoms, or for those patients not responding to outpatient management. If the diagnosis is made in the antepartum period, delivery should be strongly considered. Endomyocardial biopsy has low yield in this situation and should not be considered standard care, especially because controversy exists over the effectiveness of immunosuppressive therapy for myocarditis. Selenium, pentoxifylline, and immune globulin have all been shown to have a beneficial effect in small series of patients. The addition of these agents to standard therapy, however, should be considered on a case-by-case basis. Anticoagulation should be considered in patients with ejection fractions less than 35%. Transplantation results in survival comparable to women with idiopathic-dilated cardiomyopathy, and should be pursued in the appropriate setting. Future pregnancies should be discouraged, even if the left ventricular function recovers. Significant improvement in ventricular function can be expected in up to 50% of patients.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Richie C: Clinical contribution to the pathology, diagnosis and treatment of certain chronic diseases of the heart. Edinb Med Surg J 1849, 2:333–342.Google Scholar
  2. 2.
    Gouley BA, McMillan TM, Bellet S: Idiopathic myocardial degeneration associated with pregnancy and especially the puerperium. Am J Med Sci 1937, 19:185–199.CrossRefGoogle Scholar
  3. 3.
    Demakis JG, Rahimtoola SH: Peripartum cardiomyopathy. Circulation 1971, 44:964–968.PubMedGoogle Scholar
  4. 4.
    Whitehead SJ, Berg CJ, Chang J: Pregnancy-related mortality due to cardiomyopathy: United States, 1991–1997. Obstet Gynecol 2003, 102:1326–1331.PubMedCrossRefGoogle Scholar
  5. 5.
    Ventura SJ, Peters KD, Marting JA, et al.: Births and deaths: United States, 1996. Mon Vital Stat Rep 1997, 46(1 suppl 2):1–40.PubMedGoogle Scholar
  6. 6.
    Ansari AA, Neckelmann N, Wang YC, et al.: Immunologic dialogue between cardiac myocytes, endothelial cells, and mononuclear cells. Clin Immunol Immunopathol 1993, 68:208–214.PubMedCrossRefGoogle Scholar
  7. 7.
    Ansari AA, Fett JD, Carraway RE, et al.: Autoimmune mechanisms as the basis for human peripartum cardiomyopathy. Clin Rev Allergy Immunol 2002, 23:310–324.Google Scholar
  8. 8.
    Melvin KR, Richardson PJ, Olsen EG, et al.: Peripartum cardiomyopathy due to myocarditis. N Engl J Med 1982, 307:731–734.PubMedCrossRefGoogle Scholar
  9. 9.
    Midei MG, DeMent SH, Feldman AM, et al.: Peripartum myocarditis and cardiomyopathy. Circulation 1990, 81:922–928.PubMedGoogle Scholar
  10. 10.
    Borczuk AC, van HoevenKH, Factor SM: Review and hypothesis: the eosinophil and peripartum heart disease (myocarditis and coronary artery dissection)—coincidence or pathogenetic significance? Cardiovasc Res 1997, 33:527–532.PubMedCrossRefGoogle Scholar
  11. 11.
    Cenac A, Simionoff M, Moretto P, et al.: A low plasma selenium is a risk factor for peripartum cardiomyopathy. A comparative study in Sahelian Africa. Int J Cardiol 1992, 36:57–59.PubMedCrossRefGoogle Scholar
  12. 12.
    PearsonGD, Veille JC, Rahimtoola S, et al.: Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) Workshop recommendations and review. JAMA 2000, 283:1183–1188. A major report on recommendations for the treatment and review of pathogenesis of peripartum cardiomyopathy.PubMedCrossRefGoogle Scholar
  13. 13.
    Mann DL: Stress activated cytokines and the heart. Cytokine Growth Factor Rev 1996, 7:341–354.PubMedCrossRefGoogle Scholar
  14. 14.
    Coulson CC, Thorp JM, Mayer DC: Central hemodynamic effects of recombinant human relaxin in the isolated, perfused rat heart model. Obstet Gynecol 1996, 87:610–612.PubMedCrossRefGoogle Scholar
  15. 15.
    Demakis JG, Rahimtoola SH, Sutton GC, et al.: Natural course of peripartum cardiomyopathy. Circulation 1971, 44:1053–1061.PubMedGoogle Scholar
  16. 16.
    Garg A, Shiau J, Guyatt G: The ineffectiveness of immunosuppressive therapy in lymphocytic myocarditis: an overview. Ann Intern Med 1998, 129:317–322.PubMedGoogle Scholar
  17. 17.
    Feldman AM, McNamara D: Medical progress: myocarditis. N Engl J Med 2000, 343:1388–1398. An excellent review of the pathology, diagnosis, and treatment of myocarditis. Highlights the evidence regarding the lack of benefit of immunosuppression for treatment.PubMedCrossRefGoogle Scholar
  18. 18.
    Homans DC: Peripartum cardiomyopathy. N Engl J Med 1985, 312:1432–1437.PubMedCrossRefGoogle Scholar
  19. 19.
    Felker GM, Jaeger CJ, Klodas E, et al.: Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000, 140:785–789.PubMedCrossRefGoogle Scholar
  20. 20.
    Lampert MB, Weinert L, Hibbard J, et al.: Contractile reserve in patients with peripartum cardiomyopathy and recovered left ventricular function. Am J Obstet Gynecol 1997, 176:189–195.PubMedCrossRefGoogle Scholar
  21. 21.
    Elkayam U, Tummala PP, Rao K, et al.: Maternal and fetal outcomes of subsequent pregnancies in women with peripartum cardiomyopathy. N Engl J Med 2001, 344:1567–1571. An informative review of the outcomes of subsequent pregnancy in women who have had peripartum cardiomyopathy.PubMedCrossRefGoogle Scholar
  22. 22.
    Brown NJ, Vaughan DE: Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411–1420.PubMedGoogle Scholar
  23. 23.
    Cohn JN, Johnson G, Ziesche S, et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303–310.PubMedCrossRefGoogle Scholar
  24. 24.
    Lechat P, Packer M, Chalon S, et al.: Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998, 98:1184–1191.PubMedGoogle Scholar
  25. 25.
    Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709–717.PubMedCrossRefGoogle Scholar
  26. 26.
    Bozkurt B, Willaneuva FS, Holubkov R, et al.: Intravenous immune globulin in the therapy of peripartum cardiomyopathy. J Am Coll Cardiol 1999, 34:177–180.PubMedCrossRefGoogle Scholar
  27. 27.
    McNamara DM, Holubkov R, Starling RC, et al.: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103:2254–2259. Prospective, placebo-controlled trial evaluating IVIG for the treatment of dilated cardiomyopathy. Treatment with IVIG did not result in significant improvement over control subjects.PubMedGoogle Scholar
  28. 28.
    Bradham WS, Bozkurt B, Gunasinghe H, et al.: Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovasc Res 2002, 53:822–830.PubMedCrossRefGoogle Scholar
  29. 29.
    Sliwa K, Skudicky D, Candy G, et al.: The addition of pentoxifylline to conventional therapy improves outcome in patients with peripartum cardiomyopathy. Eur J Heart Fail 2002, 4:305–309. An interesting evaluation of a novel therapy for peripartum cardiomyopathy.PubMedCrossRefGoogle Scholar
  30. 30.
    Levander OA: Clinical consequences of low selenium intake and its relationship to vitamin E. Ann N Y Acad Sci 1982, 393:70–82.PubMedCrossRefGoogle Scholar
  31. 31.
    Levander OA, Beck MA: Selenium and viral virulence. Br Med Bull 1999, 55:528–533.PubMedCrossRefGoogle Scholar
  32. 32.
    Fett JD, Ansari AA, Sundstrom JB, et al.: Peripartum cardiomyopathy: a selenium disconnection and an autoimmune connection. Int J Cardiol 2002, 86:311–316.PubMedCrossRefGoogle Scholar
  33. 33.
    Epidemiologic studies on the etiologic relationship of selenium and Keshan disease [no authors listed]. Chin Med J 1979, 92:477–482.Google Scholar
  34. 34.
    Saito Y, Hashimoto T, Sasaki M, et al.: Effect of selenium deficiency on cardiac function of individuals with severe disabilities under long-term tube feeding. Dev Med Child Neurol 1998, 40:743–748.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Sabrina D. Phillips
    • 1
  • Carole A. Warnes
    • 1
  1. 1.Division of Cardiovascular DiseasesMayo ClinicRochesterUSA

Personalised recommendations